Establishment of a rat model of lumbar facet joint osteoarthritis using intraarticular injection of urinary plasminogen activator

Feng Shuang1,2, Shu-Xun Hou1, Jia-Liang Zhu1, Yan Liu1, Ying Zhou1, Chun-Li Zhang1 & Jia-Guang Tang1

1Department of Orthopaedics, The First Affiliated Hospital of General Hospital of Chinese PLA, Beijing 100048, China, 2Department of Orthopedics, The 94th Hospital of Chinese PLA, Nanchang 330002, China.

Lumbar facet joint (LFJ) osteoarthritis (OA) is an important etiology of low back pain. Several animal models of LFJ OA have been established using intraarticular injection of various chemicals. This study aimed to establish a rat model of LFJ OA using urinary plasminogen activator (uPA). Sprague-Dawley rats were treated with intraarticular injection in the L5-L6 facet joints with uPA (OA group, n = 40) or normal saline (vehicle group, n = 40). Mechanical and thermal hyperalgesia in the ipsilateral hind paws were evaluated using von Frey hairs and a thermoalgesia instrument, respectively. Toluidine blue staining, hematoxylin-eosin staining, and immunohistochemical examination of the LFJ were performed. Treatment with uPA induced cartilage damage, synovitis, and proliferation of synovial cells in the fact joints. The OA group showed significantly higher hyperalgesia in the hind paws in comparison with the vehicle group and normal controls (P < 0.05). Expression of IL-1β, TNF-α, and iNOS in the LFJ cartilage in the OA group was significantly increased (P < 0.05). A rat model of LFJ OA was successfully established using intraarticular injection of uPA. This animal model is convenient and shows good resemblance to human OA pathology.
group (n = 40) was treated with 5 μL normal saline. After injection, the needle was kept in place for 15 s before withdrawal. Then the wound was sutured. Eight rats were not specially treated and served as normal controls.

**Test of mechanical hyperalgesia.** The animals were tested for mechanical hyperalgesia using the von Frey hairs (North Coast Medical USA) before injection and on postoperative days 3, 7, 14, 28, 42, and 56 (n = 8). Animals were habituated to the wire mesh bottom cages for 30 min each day for three days before the test. A serious of von Frey hairs in ascending order of force (1.0 g, 1.4 g, 2.0 g, 4.0 g, 6.0 g, 8.0 g, 10.0 g, 15.0 g, and 26 g) were applied to the plantar surface of the ipsilateral hind paws for 6 s. If withdrawal response was not induced, the next level of von Frey hair was applied until at least 5 withdrawal occurred in 10 stimuli (50% positive). The minimal force required to elicit 50% positive response was recorded as the paw withdrawal threshold.

**Test of thermal hyperalgesia.** To evaluate the thermal hyperalgesia, the thermal withdrawal latency of the ipsilateral hind paw was tested using a thermode instrument (BW-P1-200, Ruanlong, Shanghai) before injection and on postoperative days 3, 7, 14, 28, 42, and 56 (n = 8)*. The rats were placed on a glass plate of constant temperature for 15 min before each test. The ipsilateral hind paws were irradiated by the thermode instrument from below the glass plate. The time (s) from irradiation to paw withdrawal was recorded as the thermal withdrawal latency. Each test was repeated three times with 10 min interval. To avoid skin burn, the maximum irradiation time was set as 60 s.

**Gait analysis.** Gait analysis was performed using a CatWalk system (XT10.5, Noldus, Netherlands) before injection and on postoperative days 3, 7, 14, 28, 42, and 56 (n = 8) as previously described8. Briefly, the animals were placed on a glass plate and allowed to walk through. Light was emitted from a LED and completely reflected internally in the glass plate. Contacts between the rat’s paw and the glass surface would allow light to reflect downwards, showing a sharp image of the paw print. A high-speed camera below the glass plate recorded the footprint of the rats and sent the images to the CatWalk system for analysis. The system analyzed the following parameters:

- Print area (cm²), the area of contact between the plantar surface of the ipsilateral hind paws and the glass plate;
- Stand phase (s), the duration of contact between the paw and the glass plate in one step cycle, reflecting the limb pain intensity;
- Swing phase (s), the duration of non-contact with the glass plate in one step cycle, also reflecting the limb pain intensity;
- Swing speed (cm/s), the speed of the paw movement in one step cycle, which was calculated by dividing the one step length by the swing phase.

**Toluidine blue staining.** On postoperative days 7, 14, 28, 42, and 56, eight rats were randomly chosen from the OA group and the vehicle group and euthanized by *i*·*p* overdose injection of pentobarbital sodium. The normal control group was sacrificed on postoperative day 56. The L5-L6 spine was removed en bloc, fixed in 4% paraformaldehyde for 48 hours, decalcified, and embedded in paraffin. The block was cut into 4-μm sections on the coronal plane and stained with toluidine blue. The sections were scored using the Osteoarthritis Research Society International (OARSI) histopathology grading system11,12. In this system, the grade of damage from 0 to 6 is defined as the depth of progression of OA into the cartilage and the stage of damage is defined as the horizontal extent of cartilage involvement from 0 to 4. The final score is the combined value of grade and stage (score range 0–24).

| Table 1 | Comparison of paw withdrawal threshold among the OA group, vehicle group, and normal control group (n = 8, mean ± SD, g) |
|---------|----------------------------------------------------------------------------------------------------------------------------------|
| Groups  | Before injection | Day 3     | Day 7     | Day 14    | Day 28    | Day 42    | Day 56    |
|---------|------------------|-----------|-----------|-----------|-----------|-----------|-----------|
| OA      | 17.75 ± 5.09     | 7.25 ± 1.83* | 7.75 ± 1.69* | 5.75 ± 1.67* | 10.50 ± 2.93 | 13.13 ± 2.59 | 13.75 ± 2.32 |
| Vehicle | 19.13 ± 5.69     | 11.63 ± 2.88 | 16.88 ± 6.13 | 16.38 ± 3.89 | 15.13 ± 4.94 | 17.13 ± 5.74 | 17.75 ± 5.09 |
| Normal control | 18.50 ± 6.44 | 20.5 ± 5.88  | 18.63 ± 6.99 | 17.13 ± 5.74 | 19.13 ± 5.69 | 19.88 ± 6.75 | 17.88 ± 7.04 |

*, vs the vehicle group and normal control group, P < 0.05

**Hematoxylin-eosin (HE) staining of the synovium.** To evaluate the condition of synovitis, HE staining was performed using the sections of synovium of the L5-L6 facet joints. Synovitis was scored with a 9-point scale including three criteria. The proliferation of synovial cells was scored as follows: fewer than three layers (0), three to four layers (1), five to six layers (2), and more than six layers (3). Inflammation was scored as follows: no lymphocytes infiltration (0), lymphocytes aggregation (1), lymphoid follicles (2), and lymphoid follicles with germinal center formation (3). Angiogenesis was scored as follows: none (0), mild (1), moderate (2), and severe (3).

**Immunohistochemical staining.** The sections were incubated with various rabbit-anti rat monoclonal antibodies (IL-1β, 1: 50; TNF-α, 1: 50; iNOS, 1: 200; Abcam, UK) at 4 °C overnight. Biotin-labeled goat-anti rabbit secondary antibody was added for 1 hour at room temperature. The staining was displayed using Diaminobenzidine. The positive cells were stained with brown color. The expression of the targeted molecules were calculated by multiplying the staining intensity score with the positive cell score. The staining intensity was scored as the following: no staining (0), light staining (1), moderate staining (2), and strong staining (3). The positive cells in three randomly selected field were scored as the following: <10% positive cells (0), 11–50% positive cells (2), 51–75% positive cells (3), and >75% (4).

**Statistical analysis.** Continuous data were expressed as mean ± standard deviation (SD). The data were tested to affirm normal distribution. Comparison was made using one-way ANOVA with SPSS 17.0 software (SPSS, US). P < 0.05 was regarded as statistically significant.

**Results**

**Paw withdrawal threshold.** On postoperative days 3, 7, and 14, the OA group showed significantly lower paw withdrawal threshold in comparison with the vehicle group and the normal control group (P < 0.05, Table 1), suggesting significantly increased mechanical hyperalgesia in the rats with induced LFJ OA.

**Thermal withdrawal latency.** On postoperative days 3, 7, and 14, the OA group showed significantly shorter thermal withdrawal latency in comparison with the vehicle group and the normal control group (P < 0.05, Table 2), suggesting significantly increased thermal hyperalgesia in the rats with induced LFJ OA.

**Gait analysis.** On postoperative days 3, 7, and 14, the OA group showed significantly lower print area, stand phase, swing speed, and significantly higher swing phase in comparison with the vehicle group and the normal control group (P < 0.05, Tables 3–6), suggesting significantly increased limb pay intensity in the rats with induced LFJ OA.

**Histopathologic analysis.** The toluidine blue staining, HE staining, and immunohistochemical staining results are shown in Fig. 1. Toluidine blue staining showed severe cartilage damage, cartilage erosion, and joint space narrow in the LFJ injected with uPA. HE
Table 3 | Comparison of print area among the OA group, vehicle group, and normal control group (n = 8, mean ± SD, cm²)

| Groups       | Before injection | Day 3    | Day 7    | Day 14   | Day 28   | Day 42   | Day 56   |
|--------------|------------------|----------|----------|----------|----------|----------|----------|
| OA           | 1.214 ± 0.064    | 0.998 ± 0.061* | 1.114 ± 0.072* | 0.893 ± 0.048* | 1.167 ± 0.057 | 1.175 ± 0.063 | 1.188 ± 0.059 |
| Vehicle      | 1.227 ± 0.075    | 1.124 ± 0.058   | 1.197 ± 0.063   | 1.213 ± 0.076   | 1.207 ± 0.069   | 1.223 ± 0.077  | 1.219 ± 0.071  |
| Normal control | 1.195 ± 0.069   | 1.231 ± 0.068   | 1.244 ± 0.076   | 1.198 ± 0.074   | 1.206 ± 0.072   | 1.219 ± 0.068  | 1.235 ± 0.078  |

* vs the vehicle group and normal control group, P < 0.05

Table 4 | Comparison of stand phase among the OA group, vehicle group, and normal control group (n = 8, mean ± SD, s)

| Groups       | Before injection | Day 3    | Day 7    | Day 14   | Day 28   | Day 42   | Day 56   |
|--------------|------------------|----------|----------|----------|----------|----------|----------|
| OA           | 0.332 ± 0.037    | 0.275 ± 0.013* | 0.257 ± 0.015* | 0.238 ± 0.017* | 0.286 ± 0.021* | 0.296 ± 0.018 | 0.308 ± 0.026 |
| Vehicle      | 0.325 ± 0.036    | 0.297 ± 0.018   | 0.307 ± 0.027   | 0.311 ± 0.028   | 0.316 ± 0.026   | 0.321 ± 0.037  | 0.318 ± 0.032  |
| Normal control | 0.317 ± 0.033   | 0.312 ± 0.024   | 0.321 ± 0.034   | 0.316 ± 0.028   | 0.333 ± 0.035   | 0.335 ± 0.042  | 0.326 ± 0.027  |

* vs the vehicle group and normal control group, P < 0.05

Table 5 | Comparison of swing phase among the OA group, vehicle group, and normal control group (n = 8, mean ± SD, s)

| Groups       | Before injection | Day 3    | Day 7    | Day 14   | Day 28   | Day 42   | Day 56   |
|--------------|------------------|----------|----------|----------|----------|----------|----------|
| OA           | 0.129 ± 0.008    | 0.163 ± 0.013* | 0.161 ± 0.012* | 0.183 ± 0.015* | 0.167 ± 0.017* | 0.153 ± 0.018  | 0.146 ± 0.016  |
| Vehicle      | 0.132 ± 0.011    | 0.147 ± 0.012   | 0.144 ± 0.011   | 0.138 ± 0.013   | 0.134 ± 0.009   | 0.137 ± 0.008  | 0.138 ± 0.015  |
| Normal control | 0.136 ± 0.012   | 0.133 ± 0.010   | 0.142 ± 0.009   | 0.135 ± 0.009   | 0.128 ± 0.010   | 0.140 ± 0.013  | 0.137 ± 0.011  |

* vs the vehicle group and normal control group, P < 0.05

Table 6 | Comparison of swing speed among the OA group, vehicle group, and normal control group (n = 8, mean ± SD, cm/s)

| Groups       | Before injection | Day 3    | Day 7    | Day 14   | Day 28   | Day 42   | Day 56   |
|--------------|------------------|----------|----------|----------|----------|----------|----------|
| OA           | 107.32 ± 5.76    | 84.64 ± 4.26* | 80.31 ± 6.43* | 77.85 ± 5.52* | 92.54 ± 7.58* | 97.32 ± 8.81* | 99.69 ± 9.12  |
| Vehicle      | 110.64 ± 6.21    | 99.78 ± 7.73   | 104.56 ± 8.94  | 107.84 ± 8.51  | 107.89 ± 9.23  | 108.57 ± 8.47  | 104.85 ± 6.22  |
| Normal control | 106.87 ± 6.38   | 109.52 ± 8.43  | 112.13 ± 9.65  | 105.95 ± 9.78  | 103.56 ± 8.48  | 111.21 ± 10.14 | 108.73 ± 8.83  |

* vs the vehicle group and normal control group, P < 0.05

Figure 1 | Toluidine blue staining, HE staining, and immunohistochemical staining of the LFJ. Scale bar: 100 μm.
staining showed proliferation of the synovial cells, lymphocyte infiltration, and degenerative changes in the cartilage in the OA group. The OA group showed significantly higher OARSI scores and synovitis scores than the vehicle group (P < 0.05, Table 7 and 8). The expressions of IL-1β, TNF-α, and iNOS in the cartilage were significantly increased in the OA group in comparison with the vehicle group (P < 0.05).

**Discussion**

LFJ OA has been implied to be a major contributing factor for low back pain. There has been previously reported rat models of LFJ OA established using intraarticular injection of collagenase3, monosodium iodoacetate13,14, and complete Freund’s adjuvant15. In our study, we tried to establish a rat model of LFJ OA using intraarticular injection of uPA. uPA is a serine protease and its primary physiological substrate is plasminogen. Plasminogen is an inactive form (zymogen) of the serine protease plasmin. Activation of plasmin triggers a proteolysis cascade that, depending on the physiological environment, participates in thrombolysis or extracellular matrix degradation16,17. It has been found that uPA plays important roles in the degradation of extracellular matrix in the osteoarthritic cartilage3, and levels of uPA in the articular cartilage and synovium are associated with the severity of cartilage damage18. Regarding the pathological roles of uPA in OA, we speculate that uPA might be a good candidate for the establishment of animal models of LFJ OA. In our study, we injected uPA into the articular space of L5-L6 facet joint in rats. Histopathologic examination showed that uPA-induced synovitis and cartilage degeneration in the LFJ, which mimics the pathological changes in human OA. In comparison with Freund’s adjuvant, uPA was milder and this uPA-induced model can reflect the complete pathological process of LFJ OA of its early, middle, and late phases. Therefore, the uPA-induced model might be more useful for the development of therapeutic methods targeting the early and middle phases of LFJ OA.

Mechanical hyperalgesia was found in a rat model of LFJ OA induced by intraarticular injection of complete Freund’s adjuvant15. In addition, concomitant pain-related behavioral changes were also noticed. It is suggested that facet joint inflammation, and not degeneration of the joint, might have been a cause of the hyperalgesia. In our study, both mechanical and thermal hyperalgesia were tested to gain further insight into this issue. We found that intraarticular injection of uPA into the LFJ in rats significantly decreased the paw withdrawal threshold and thermal withdrawal latency, indicating the presence of mechanical and thermal hyperalgesia. Gait analysis also found that the animal behaviors showed significant changes in the OA group. The specific mechanisms underlying the hyperalgesia and gait changes are not clear. Our results indicate that some inflammatory factories might play a role. IL-1β is involved in the development neuropathic pain, and can also increase the sensitivity of the spine to pain stimuli19. The expression of TNF-α and iNOS in the LFJ cartilage in rats with induced LFJ OA was also increased. IL-1β and TNF-α are scarcely expressed in normal facet joints and are associated with the inflammation severity in LFJ OA. iNOS can induce the synthesis of NO in OA conditions, and NO is involved in the apoptosis of chondrocytes20. Chondrocytes apoptosis can lead to cartilage damage and destabilized facet joint structure.

In conclusion, we successfully established a rat model of LFJ OA using intraarticular injection of uPA. This animal model is convenient and shows good resemblance of human facet joint OA pathology. Further investigation is needed to find out the mechanisms of hyperalgesia in this animal model.

**Table 7** Comparison of OARSI scores between the OA group and the vehicle group (n = 8, mean ± SD)

| Groups | Day 7  | Day 14 | Day 28 | Day 42 | Day 56 |
|--------|--------|--------|--------|--------|--------|
| OA     | 1.75 ± 0.46* | 5.75 ± 1.67* | 8.13 ± 0.99* | 12.50 ± 2.33* | 17.50 ± 1.69* |
| Vehicle | 0      | 0      | 0      | 0.25 ± 0.46 | 0.50 ± 0.54 |

*, vs the vehicle group, P < 0.05

**Table 8** Comparison of synovitis scores between the OA group and the vehicle group (n = 8, mean ± SD)

| Groups | Day 7  | Day 14 | Day 28 | Day 42 | Day 56 |
|--------|--------|--------|--------|--------|--------|
| OA     | 2.75 ± 0.71* | 3.88 ± 0.64* | 6.75 ± 0.71* | 5.00 ± 0.76* | 4.13 ± 0.84* |
| Vehicle | 0.25 ± 0.46 | 0.50 ± 0.54 | 0.38 ± 0.54 | 0.63 ± 0.52 | 0.50 ± 0.54 |

*, vs the vehicle group, P < 0.05

1. Gelhorn, A. C., Katz, J. N. & Suri, P. Osteoarthritis of the spine: the facet joints. *Nat. Rev. Rheumatol.* 9, 216–224 (2013).
2. Schwarzer, A. C., Wang, S. C., Bogduk, N., McNaught, P. J. & Laurent, R. Prevalence and clinical features of lumbar zygapophysial joint pain: a study in an Australian population with chronic low back pain. *Ann. Rheum. Dis.* 54, 100–106 (1995).
3. Schwarzer, A. C. et al. Clinical features of patients with pain stemming from the lumbar zygapophysial joints. In *The lumbar facet syndrome: a clinical entity?* Spine (Phila Pa 1976). 19, 1132–1137 (1994).
4. Kirkaldy-Willis, W. H. & Farfan, H. F. Instability of the lumbar spine. *Clin. Orthop. Relat. Res.* 165, 110–123 (1982).
5. Yeh, T. T. et al. Intra-articular injection of collagenase induced experimental osteoarthritis of the lumbar facet joint in rats. *Eur. Spine J.* 17, 734–742 (2008).
6. Del Rosso, M., Fisbi, G. & Matucci Cerinic, M. The urokinase-type plasminogenactivator system and inflammatory joint diseases. *Clin. Exp. Rheumatol.* 17, 485–498 (1999).
7. Yang, S. F. et al. Effects of nonsteroidal anti-inflammatory drugs on the expression of urokinase plasminogen activator and inhibitor and gelatinases in the early osteoarthritic knee of humans. *Clin. Biochem.* 41, 109–116 (2008).
8. Couto, M. Laboratory guidelines for animal care. *Methods. Mol. Biol.* 770, 579–599 (2011).
9. Hargreaves, K., Dubner, R., Brown, F., Flores, C. & Joris, J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. *Pain.* 32, 77–88 (1988).
10. Gabriel, A. F., Marcus, M. A., Walenkamp, G. H. & Joosten, E. A. The OARSI histopathology initiative: recommendations for histological assessments of osteoarthritis in the rat. *Osteoarthritis Cartilage.* 18, S24–S30 (2010).
11. Pritzker, K. P. et al. Osteoarthritis cartilage histopathology: grading and staging. *Osteoarthritis Cartilage.* 14, 13–29 (2006).
12. Gerwin, N., Bendele, A. M., Glasson, S. & Carlson, C. S. The OARSI histopathology initiative: recommendations for histological assessments of osteoarthritis in the rat. *Osteoarthritis Cartilage.* 18, S24–S30 (2010).
13. Gong, K., Shao, W., Chen, H., Wang, Z. & Luo, Z. J. Rat model of lumbar facet joint osteoarthritis associated with facet-mediated mechanical hyperalgesia induced by intra-articular injection of monosodium iodoacetate. *J. Formos. Med. Assoc.* 110, 145–152 (2011).
14. Kim, J. S. et al. Characterization of a new animal model for evaluation and treatment of back pain due to lumbar facet joint osteoarthritis. *Arthritis Rheum.* 63, 2966–2973 (2011).
15. Shuang, F. et al. Establishment of a Rat Model of Adjuvant-Induced Osteoarthritis of the Lumbar Facet Joint. *Cell Biochem. Biophys.* (2014) doi: 10.1007/s12013-014-0091-5.
16. Andreasen, P. A., Kjoller, L., Christensen, L. & Duffy, M. J. The urokinase-type plasminogen activator system in cancer metastasis: a review. *Int. J. Cancer.* 72, 1–22 (1997).

17. Conn, E. M. *et al.* Comparative analysis of metastasis variants derived from human prostate carcinoma cells: roles in intravasation of VEGF-mediated angiogenesis and uPA-mediated invasion. *Am. J. Pathol.* 175, 1638–1652 (2009).

18. Nakano, S., Ikata, T., Kinoshita, I., Kanematsu, J. & Yasuoka, S. Characteristics of the protease activity in synovial fluid from patients with rheumatoid arthritis and osteoarthritis. *Clin. Exp. Rheumatol.* 17, 161–170 (1999).

19. Apkarian, A. V. *et al.* Expression of IL-1beta in supraspinal brain regions in rats with neuropathic pain. *Neurosci. Lett.* 407, 176–181 (2006).

20. Ozaki, D. *et al.* Transduction of anti-apoptotic proteins into chondrocytes in cartilage slice culture. *Biochem. Biophys. Res. Commun.* 313, 522–527 (2004).

**Author contribution**

F.S. and S.X.H. wrote the main manuscript text, J.L.Z., Y.L. and Y.Z. collected data and carried out the experiments, C.L.Z. analyzed the data, J.G.T. designed the experiments. All author has approved the manuscript.

**Additional information**

Supplementary information accompanies this paper at http://www.nature.com/scientificreports

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Shuang, F. *et al.* Establishment of a rat model of lumbar facet joint osteoarthritis using intraarticular injection of urinary plasminogen activator. *Sci. Rep.* 5, 9828; DOI:10.1038/srep09828 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/